Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Mineralys Therapeutics Inc shares valued at $175,237 were sold by Congleton Jon on Jun 20 ’24. At $11.73 per share, Congleton Jon sold 14,940 shares. The insider’s holdings dropped to 926,958 shares worth approximately $11.26 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Congleton Jon sold 16,607 shares, netting a total of over 199,073 in proceeds. Following the sale of shares at $11.99 each, the insider now holds 941,898 shares.
Before that, Congleton Jon had sold 17,766 shares from its account. In a trade valued at $217,712, the Chief Executive Officer traded Mineralys Therapeutics Inc shares for $12.25 each. Upon closing the transaction, the insider’s holdings decreased to 17,766 shares, worth approximately $11.65 million.
As published in their initiating research note from Goldman on April 02, 2024, Mineralys Therapeutics Inc [MLYS] has been a Buy and the price target has been revised to $30. Analysts at Wells Fargo started covering the stock with ‘”an Overweight”‘ outlook in a report released in early March. As of March 07, 2023, Stifel has initiated its “Buy” rating for MLYS. Earlier on March 07, 2023, Guggenheim initiated its rating. Their recommendation was “a Buy” for MLYS stock.
Analyzing MLYS Stock Performance
During the last five days, there has been a surge of approximately 9.56%. Over the course of the year, Mineralys Therapeutics Inc shares have jumped approximately 41.28%. Shares of the company reached a 52-week high of $16.91 on 02/27/24 and a 52-week low of $7.95 on 01/18/24. A 50-day SMA is recorded $12.62, while a 200-day SMA reached $10.90. Nevertheless, trading volume fell to 88033.0 shares from 0.2 million shares the previous day.
Support And Resistance Levels for Mineralys Therapeutics Inc (MLYS)
According to the 24-hour chart, there is a support level at 11.97, which, if violated, would cause prices to drop to 11.78. In the upper region, resistance lies at 12.37. The next price resistance is at 12.58. RSI (Relative Strength Index) is 47.97 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.10, which suggests the price will decrease in the coming days. Percent R is at 44.50%, indicating low price movement. Stochastics%K at holding indicates that the stock is to be held.
